These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor. Kaplan FM; Kugel CH; Dadpey N; Shao Y; Abel EV; Aplin AE J Biol Chem; 2012 Dec; 287(50):41797-807. PubMed ID: 23076151 [TBL] [Abstract][Full Text] [Related]
9. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471 [TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Wong DJ; Robert L; Atefi MS; Lassen A; Avarappatt G; Cerniglia M; Avramis E; Tsoi J; Foulad D; Graeber TG; Comin-Anduix B; Samatar A; Lo RS; Ribas A Mol Cancer; 2014 Aug; 13():194. PubMed ID: 25142146 [TBL] [Abstract][Full Text] [Related]
11. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329 [TBL] [Abstract][Full Text] [Related]
12. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212 [TBL] [Abstract][Full Text] [Related]
13. BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600Ε CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis. Koumaki K; Kontogianni G; Kosmidou V; Pahitsa F; Kritsi E; Zervou M; Chatziioannou A; Souliotis VL; Papadodima O; Pintzas A Biochim Biophys Acta Mol Basis Dis; 2021 Apr; 1867(4):166061. PubMed ID: 33385518 [TBL] [Abstract][Full Text] [Related]
14. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Shi H; Kong X; Ribas A; Lo RS Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746 [TBL] [Abstract][Full Text] [Related]
15. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143 [TBL] [Abstract][Full Text] [Related]
16. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965 [TBL] [Abstract][Full Text] [Related]
17. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Fedorenko IV; Fang B; Munko AC; Gibney GT; Koomen JM; Smalley KS Proteomics; 2015 Jan; 15(2-3):327-39. PubMed ID: 25339196 [TBL] [Abstract][Full Text] [Related]
18. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Roskoski R Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796 [TBL] [Abstract][Full Text] [Related]
19. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
20. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model. Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]